Jefferies analyst Sean Dodge believes the 15% selloff in shares of Healthcare Services Group on the Chapter 11 filing of client Senior Care Centers is “way overblown.” After traveling with management, the analyst says he learned Healthcare Services is well positioned to recover all money it’s owed and should keep all services in place. Also notable, manager recruiting has resumed, paving the way for a second half of 2019 re-acceleration in revenue growth, Dodge tells investors in a research note. He keeps a Buy rating on Healthcare Services Group with a $52 price target.
Friday, December 14, 2018
Centene to hold a meeting
2019 Financial Guidance & Investor Day will be held in New York on December 14 at 8:30 am.
Pfizer initiates Phase 3 program for 20-Valent pneumococcal conjugate vaccine
Pfizer announced the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine candidate, PF-06482077, for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older. This first Phase 3 trial will enroll an estimated 3,880 adults and is designed to compare immune responses after 20vPnC administration to responses in control subjects greater than or equal to60 years old receiving 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine; evaluate the immunogenicity of 20vPnC in adults 18-59 years of age; and describe the 20vPnC safety profile in adults greater than or equal to18 years old. More on the study can be found on http://www.clinicaltrials.gov under the identifier NCT03760146.
Idera Pharmaceuticals to host conference call
Conference call to discuss ILLUMINATE-204 clinical data will be held on December 14 at 10 am.
J&J knew ‘for decades’ of asbestos in baby powder, Reuters reports
According to a Reuters examination of documents for some of the 11,700 plaintiffs now claiming that Johnson & Johnson’s talc caused their cancers, J&J knew for decades that asbestos had been found in its talc products, that from at least 1971 to the early 2000s, the company’s raw talc and finished powders sometimes tested positive for small amounts of asbestos, and that company executives, mine managers, scientists, doctors and lawyers fretted over the problem and how to address it while failing to disclose it to regulators or the public. Johnson & Johnson failed to tell the FDA that at least three tests by three different labs from 1972 to 1975 had found asbestos in its talc — in one case at levels reported as “rather high,” Reuters reports. In response to Reuters’ findings, Ernie Knewitz, J&J’s vice president of global media relations, wrote that “This is all a calculated attempt to distract from the fact that thousands of independent tests prove our talc does not contain asbestos or cause cancer. Any suggestion that Johnson & Johnson knew or hid information about the safety of talc is false.”
https://thefly.com/landingPageNews.php?id=2837379
Eli Lilly to host guidance and investment community meeting
2019 Guidance and Investment Community Meeting will be held on December 19 at 9 am
Argenx initiated at Wolfe Research
Argenx initiated with an Outperform at Wolfe Research
https://thefly.com/landingPageNews.php?id=2837385
Subscribe to:
Posts (Atom)